Clin2
NCT06706674Possibly a fitRecruiting

Testing lumateperone for irritability in teens with autism

Irritability Associated With Autism Spectrum Disorder

Part of Brain & nervous system, Mental health clinical trials.

This study tests an investigational medication called lumateperone to see if it can reduce irritability in children and teens with autism. It is for teenagers aged 13–17 whose irritability is causing significant problems.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
160 people
Ages
5 years to 17 years
Study type
Interventional

Who can take part

  • The child must be between 13 and 17 years old (currently only teens are being enrolled).
  • They must have a confirmed autism diagnosis with significant irritability that affects daily life.
  • A parent or guardian must be willing to take part in study visits and answer questions about the child.
  • If the child has ADHD, their ADHD medications must have been stable for at least 30 days before the study starts.
  • The child must not have serious thoughts of self-harm or suicide, and no diagnosis of Rett or Fragile X syndrome.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06690398Recruiting· Phase 3
Study of Lumateperone for Autism-Related Irritability in Teens

This study tests a new medication called Lumateperone to see if it can reduce irritability in children and teens with autism. It's a 3-month trial that compares the study drug to a placebo (a pill with no active medicine) to find out if it helps with mood and behavior.

Dothan, Alabama
NCT07284745Not yet recruiting· Phase 3
Study of KarXT + KarX-EC for autism-related irritability in kids

This trial tests whether a combination of two medications (KarXT and KarX-EC) can help reduce irritability in children and teens with autism. It's for those who have significant irritability symptoms that affect daily life.

Dothan, Alabama
NCT07285798Not yet recruiting· Phase 3
Study of KarXT plus KarX-EC for irritability in children with autism

This trial tests a combination of two drugs, KarXT and KarX-EC, to see if they can reduce irritability in children and teens with autism spectrum disorder. If your child has significant irritability linked to their autism, this study may offer a new treatment option.

Phoenix, Arizona
NCT06229210Recruiting· Phase 3
Lumateperone safety study for children with schizophrenia, bipolar, or autism

This trial tests a medication called lumateperone for children and teens with schizophrenia, bipolar disorder, or autism spectrum disorder. It aims to see if the medicine is safe and tolerable over time.

Phoenix, Arizona
NCT06372964Recruiting· Phase 3
Lumateperone for pediatric bipolar depression

This study tests a new medication called lumateperone for treating depression in children and teens with bipolar disorder. It aims to see if this drug can help improve mood and daily functioning.

Dothan, Alabama
NCT06482554Recruiting· Phase 3
Lumateperone for Apathy in Psychotic Disorders

This trial tests a medication called lumateperone to see if it can improve apathy (lack of motivation) in people who have psychotic symptoms from schizophrenia or related disorders. It may help if you are already on a stable treatment but still struggle with apathy.

Shreveport, Louisiana

Hear when a new Irritability Associated With Autism Spectrum Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.